Comparison of oxytocin/prostaglandin F-2 alpha interrelationships in cyclic and pregnant cows.
The secretion of prostaglandin (PG) F-2 alpha in response to intravenous injection of 100 i.u. oxytocin on Day 18 after oestrus was determined by measuring jugular venous concentrations of 13,14-dihydro-15-keto PGF-2 alpha (PGFM) in 7 pregnant, 6 cyclic and 2 inseminated non-pregnant heifers. Two other heifers received i.v. saline (controls). The immediate responses of pregnant heifers were smaller than in non-pregnant animals (P less than 0.05), as were baseline concentrations in the post-response period (P less than 0.05). Endometrial oxytocin receptor concentrations were higher in nonpregnant than pregnant heifers (P less than 0.05), but PGFM response to oxytocin challenge was not correlated with oxytocin receptor concentration. Oxytocin receptor concentrations on Day 18 were positively correlated with those of plasma oestradiol on Day 17 (P less than 0.01) and inversely with plasma progesterone concentrations on Day 18 (P less than 0.01). These findings confirm that PGF-2 alpha secretion in response to oxytocin challenge is attenuated in pregnant animals on the 18th day after oestrus and that, while the prevailing steroid environment is of importance in inducing oxytocin receptor activity, the secretion of PGF-2 alpha is not subsequently limited by oxytocin receptor numbers. The quantities of PGE-2, PGFM and PGF-2 alpha recovered in uterine flushings taken from heifers on Day 18 were greater in pregnant than other animals (P less than 0.01, P less than 0.05, P less than 0.001, respectively). Intrauterine concentrations of PGF-2 alpha and PGFM were not correlated with the plasma PGFM responses.
Parkinson
T J
TJ
AFRC Research Group on Hormones and Farm Animal Reproduction, University of Nottingham, School of Agriculture, Loughborough, Leics, UK.
Jenner
L J
LJ
Lamming
G E
GE
D000818:Animals; D002417:Cattle / Q000502:physiology*; D015237:Dinoprost / Q000031:analogs & derivatives / Q000032:analysis / Q000097:blood / Q000378:metabolism*; D015232:Dinoprostone / Q000032:analysis; D004958:Estradiol / Q000097:blood; D004971:Estrus / Q000502:physiology*; D005260:Female; D010121:Oxytocin / Q000494:pharmacology / Q000502:physiology*; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000502:physiology*; D011374:Progesterone / Q000097:blood; D011945:Receptors, Angiotensin / Q000378:metabolism; D018045:Receptors, Oxytocin; D014599:Uterus / Q000378:metabolism
D011945:Receptors, Angiotensin; D018045:Receptors, Oxytocin; C008228:15-keto-13,14-dihydroprostaglandin F2alpha; D011374:Progesterone; D004958:Estradiol; D010121:Oxytocin; D015237:Dinoprost; D015232:Dinoprostone